Moderate Evidence
Research Overview
VK2735 Research for Obesity
An evidence-based overview of research examining VK2735 in the context of obesity. This page synthesizes findings from peer-reviewed literature.
Research Summary
VK2735 is in Phase 3 development for obesity treatment. VENTURE Phase 2 demonstrated 14.7% weight loss at 13 weeks with subcutaneous administration. VANQUISH-1 Phase 3 trial has enrolled 4,650 patients for 78-week evaluation.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Obesity
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. VK2735 may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.